Tech Company Financing Transactions
Tricida Funding Round
Tricida, based in South San Francisco, raised $30 million from OrbiMed and private investors.
Transaction Overview
Company Name
Announced On
3/5/2015
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series B
Investors
OrbiMed (Lead Investor) (David Bonita)
Proceeds Purpose
Tricida's clinical lead candidate, TRC101, is on track for an IND submission later this year. I am excited by our rapid progress that has allowed us to advance TRC101 from discovery into development in record time.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
7000 Shoreline Ct. 201
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Tricida, Inc. is an innovative startup company focused on the discovery and clinical development of novel therapeutics to address renal, metabolic and cardiovascular disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gerrit Klaerner
Chief Financial Officer
Geoffrey Parker
Chief Technical Officer
Wilhelm Stahl
Vice President
Dawn Parsell
VP - Bus. Development
Claire Lockey
VP - General Counsel
Edward Hejlek
Browse more venture capital transactions:
Prev: 3/5/2015: Semprius venture capital transaction
Next: 3/5/2015: Aura Biosciences venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs